6 Analysts Assess Absci: What You Need To Know
Portfolio Pulse from Benzinga Insights
Six analysts have recently assessed Absci (NASDAQ:ABSI), showing a mix of bullish and somewhat bullish ratings with an average 12-month price target of $8.17, a significant increase from the previous $4.00. Absci, an AI-powered synthetic biology company, has seen a revenue decline of -68.59% over the past 3 months, with a net margin of -2956.18%, ROE of -10.68%, and ROA of -8.97%. Despite the financial challenges, the company's market position remains strong with a low debt-to-equity ratio of 0.09.
March 22, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci has received mixed analyst ratings but a significantly higher average price target of $8.17, indicating a positive outlook despite recent financial challenges.
The increase in the average price target to $8.17 from $4.00, despite a -68.59% revenue decline and a net margin of -2956.18%, suggests analysts see potential recovery or growth opportunities for Absci. The bullish and somewhat bullish ratings from analysts further support a positive short-term outlook for ABSI's stock price. However, the financial challenges highlighted, such as the significant revenue decline and negative ROE and ROA, introduce caution, hence the importance and confidence scores.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100